ArticleJournal of thoracic disease2026
Pulmonary amyloidosis: clinicopathologic spectrum and diagnostic pitfalls in a 12-patient case series.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary amyloidosis is a rare, underrecognized manifestation of amyloid disease that may present as nodular, tracheobronchial, or diffuse alveolar-septal involvement and can mimic common pulmonary conditions. This study aimed to characterize the clinicopathologic features, diagnostic patterns, and management approaches of patients with pulmonary amyloidosis in a real-world setting. Methods: We performed a retrospective review of patients with pathology-confirmed pulmonary amyloidosis diagnosed between January 2020 and December 2024 at a tertiary academic medical center in Detroit, Michigan. Data included demographics, presenting symptoms, imaging and histopathologic findings, amyloid typing, treatment, and outcomes. Results: Twelve patients were included (median age 76 years; 50% female; 42% Black); 67% were former smokers. Nodular pulmonary amyloidosis was the predominant pattern (92%), and half of cases were diagnosed incidentally (50%). Amyloid typing was completed in 25% [immunoglobulin light-chain amyloidosis (AL) 17%, transthyretin-related amyloidosis (ATTR) 8%]; typing was incomplete or not performed in the remainder due to ongoing evaluation, patient preference, loss to follow-up, or death. Management was heterogeneous, including systemic therapy (25%), surgical resection with surveillance (8%), and supportive/palliative care (8%); several patients were undergoing evaluation at last follow-up. At analysis, 75% were alive at the last known follow-up. Conclusions: Pulmonary amyloidosis commonly presents as nodular disease and is frequently detected incidentally. Incomplete amyloid typing and variable management highlight diagnostic and care gaps. Systematic amyloid subtyping is essential to guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.